Skip to main content
. Author manuscript; available in PMC: 2021 Sep 16.
Published in final edited form as: J Am Chem Soc. 2020 Sep 4;142(37):16039–16050. doi: 10.1021/jacs.0c07433

Figure 1.

Figure 1.

Top: Structure of vancomycin and key analogues with H-bonding interactions between vancomycin and model ligands indicated by dashed lines. Middle: Added peripheral modifications that synergistically improve activity by inducing membrane permeabilization (C1) or directly inhibiting transglycosylase (CBP), both independent of D-Ala-D-Ala/D-Lac binding. Bottom: VanA VRE antimicrobial activity.